Mersana Therapeutics, Inc.
mersana.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q3 FY2025 10-Q, filed Nov 14, 2025. Its latest SEC filing is a SCHEDULE 13G/A from May 15, 2026.
10-Q for Q3 FY2025, filed Nov 14, 2025
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Develops antibody-drug conjugates for cancer patients and works with pharmaceutical collaborators to create additional drug candidates.
10-K for FY2024, filed Mar 3, 2025
How Did They Make Money?
Receives collaboration payments from pharmaceutical partners for licenses to its technology and product candidates and for research and development work; payments may include upfront fees, cost reimbursements, milestones, and royalties on licensed-product sales.
10-K for FY2024, filed Mar 3, 2025
$40.5M
-
10-K for FY2024, filed Mar 3, 2025
$40.5M ↗
Who Were Their Customers?
Works with pharmaceutical companies as research and development collaborators; Johnson & Johnson and Merck KGaA have platform collaborations, while GSK holds an option to co-develop and commercialize XMT-2056.
10-K for FY2024, filed Mar 3, 2025
Did Revenues Turn Into Profits?
No. It lost $69.2M in FY2024.
How Were They Changing?
-
Jan 6, 2026
Day One completed its acquisition of Mersana
Mersana became a wholly owned subsidiary of Day One; its incumbent officers, including the CEO, left their roles.
Sources
8-K, filed Jan 6, 2026
As a result of the consummation of the Offer and the consummation of the Merger in accordance with Section 251(h) of the DGCL on January 6…View ↗
Grew. Revenue grew 48.9x in 4 years, from $828K in FY2020 to $40.5M in FY2024, about 164% a year.
Pipeline priorities
The older report centered its clinical strategy on UpRi for ovarian cancer; the latest describes clinical work on Emi-Le and an immune-stimulating candidate, while saying UpRi development had ended.
10-K for FY2021, filed Feb 28, 2022 10-K for FY2024, filed Mar 3, 2025Strive to Build UpRi (upifitamab rilsodotin) into a Foundational Medicine in Ovarian Cancer. Our lead product candidate, upifitamab…View ↗
Who Did They Compete With?
Competes with AbbVie, Daiichi Sankyo, Gilead Sciences, Johnson & Johnson, Pfizer, Astellas Pharma, AstraZeneca, Genentech, Takeda, GSK, Hansoh Pharmaceutical Group, BeiGene, Duality Biologics, NextCure, LigaChem Biosciences, ABL Bio, Bicycle Therapeutics, Oncolytics Biotech, Bolt Biotherapeutics, and Sutro Biopharma
10-K for FY2024, filed Mar 3, 2025Companies with cytotoxic ADC platforms: Many companies are investing in innovation in the ADC field, including new payload classes, new…View ↗
Loading...
